Contrasting Accelerate Diagnostics (AXDX) and Hansen Medical (HNSN)

Accelerate Diagnostics (NASDAQ: AXDX) and Hansen Medical (NASDAQ:HNSN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Accelerate Diagnostics and Hansen Medical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $1.29 million 859.17 -$61.92 million ($1.23) -17.32
Hansen Medical N/A N/A N/A N/A N/A

Hansen Medical has higher revenue, but lower earnings than Accelerate Diagnostics.

Institutional and Insider Ownership

38.5% of Accelerate Diagnostics shares are owned by institutional investors. 51.4% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Accelerate Diagnostics has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, Hansen Medical has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Accelerate Diagnostics and Hansen Medical, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 0 2 0 3.00
Hansen Medical 0 0 0 0 N/A

Accelerate Diagnostics presently has a consensus target price of $33.00, indicating a potential upside of 54.93%. Given Accelerate Diagnostics’ higher probable upside, equities analysts plainly believe Accelerate Diagnostics is more favorable than Hansen Medical.


This table compares Accelerate Diagnostics and Hansen Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -5,062.48% -67.44% -63.75%
Hansen Medical -317.95% N/A -96.52%


Accelerate Diagnostics beats Hansen Medical on 7 of the 9 factors compared between the two stocks.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

About Hansen Medical

Hansen Medical, Inc. is engaged in the development and marketing of medical devices. The Company develops, manufactures and sells a range of medical robotics designed for positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System (Sensei system), Artisan Extend Control Catheter, CoHesion 3D Visualization Module and Magellan System. Its Sensei system allows physicians to navigate catheters in interventional procedures within the atrial heart chambers. Its disposable Artisan Extend catheter assembly consists of a telescoping set of control catheters. Its CoHesion 3D Visualization Module is a software interface between its Sensei system and the St. Jude Medical EnSite System for Electro-Physiology procedures. The Magellan System controls the Magellan Robotic Catheter, which is a telescoping, steerable catheter designed to facilitate remote catheter navigation and vessel cannulation.

What are top analysts saying about Accelerate Diagnostics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Accelerate Diagnostics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit